...
首页> 外文期刊>Journal of Molecular Structure >The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of in silico methods for treatment of COVID-19
【24h】

The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of in silico methods for treatment of COVID-19

机译:SARS-COV-2人血管紧张素转化酶2和主要蛋白酶的新抑制剂的鉴定:硅藻方法的组合治疗Covid-19

获取原文
获取原文并翻译 | 示例
           

摘要

The angiotensin-converting enzyme 2 (ACE2) and main protease (MPro), are the putative drug candidates for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we performed 3D-QSAR pharmacophore modeling and screened 1,264,479 ligands gathered from Pubchem and Zinc databases. Following the calculation of the ADMET properties, molecular docking was carried out. Moreover, the de novo ligand design was performed. MD simulation was then applied to survey the behavior of the ligand-protein complexes. Furthermore, MMPBSA has utilized to re-estimate the binding affinities. Then, a free energy landscape was used to find the most stable conformation of the complexes. Finally, the hybrid QM-MM method was carried out for the precise calculation of the energies.
机译:血管紧张素转换酶2(ACE2)和主要蛋白酶(MPro)是严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的候选药物。在本研究中,我们进行了3D-QSAR药效团建模,并从Pubchem和Zn数据库中筛选了1264479个配体。在计算ADMET性质之后,进行了分子对接。此外,还进行了从头配体设计。然后应用MD模拟研究配体-蛋白质复合物的行为。此外,MMPBSA还用于重新估计结合亲和力。然后,利用自由能图来寻找配合物最稳定的构象。最后,采用混合QM-MM方法对能量进行了精确计算。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号